A Unique Presentation of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Foot Drop in
Adelyn D Souza1, Chinmay Patel2, Karthick N Vijayaraghavan3
1Department of Hematology, K. S. Hegde Medical Academy, Mangalore, IND.
Central nervous system (CNS) involvement in adult B-cell acute lymphoblastic leukemia (B-ALL) continues to pose treatment challenges, even with advancements in chemotherapy and targeted immunotherapy. Blinatumomab, a bispecific T-cell engager, has been shown to improve outcomes for patients with relapsed or refractory B-ALL; however, it can lead to immune-related neurotoxic effects, including immune effector cell-associated neurotoxicity syndrome (ICANS). We present an unusual case of a 38-year-old man with refractory B-ALL who experienced a parenchymal CNS relapse that manifested as foot drop during treatment with blinatumomab, likely as a result of ICANS. Initially, the patient achieved a remission with no minimal residual disease after undergoing R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and intrathecal chemotherapy. Unfortunately, he later relapsed with CNS involvement confirmed by imaging and biopsy. Following salvage therapy that included blinatumomab, he developed acute neurotoxic symptoms and peripheral neuropathy, which did not improve despite treatment. This case illustrates the complexities of CNS relapse in B-ALL and highlights a rare occurrence of neurotoxicity associated with blinatumomab, stressing the importance of awareness and prompt management of such complications.
Central nervous system (CNS) involvement in adult B-cell acute lymphoblastic leukemia (B-ALL) continues to pose treatment challenges, even with advancements in chemotherapy and targeted immunotherapy. Blinatumomab, a bispecific T-cell engager, has been shown to improve outcomes for patients with relapsed or refractory B-ALL; however, it can lead to immune-related neurotoxic effects, including immune effector cell-associated neurotoxicity syndrome (ICANS). We present an unusual case of a 38-year-old man with refractory B-ALL who experienced a parenchymal CNS relapse that manifested as foot drop during treatment with blinatumomab, likely as a result of ICANS. Initially, the patient achieved a remission with no minimal residual disease after undergoing R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and intrathecal chemotherapy. Unfortunately, he later relapsed with CNS involvement confirmed by imaging and biopsy. Following salvage therapy that included blinatumomab, he developed acute neurotoxic symptoms and peripheral neuropathy, which did not improve despite treatment. This case illustrates the complexities of CNS relapse in B-ALL and highlights a rare occurrence of neurotoxicity associated with blinatumomab, stressing the importance of awareness and prompt management of such complications.
More Related Videos
09:01Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
Published on: November 17, 2020
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
01:26Encephalitis ll: Pathophysiology